Home >> Research Area >>Natural Products>>Lignans>> Pinoresinol 4-O-beta-D-glucopyranoside

Pinoresinol 4-O-beta-D-glucopyranoside

CAS# 69251-96-3

Pinoresinol 4-O-beta-D-glucopyranoside

2D Structure

Catalog No. BCN1376----Order now to get a substantial discount!

Product Name & Size Price Stock
Pinoresinol 4-O-beta-D-glucopyranoside: 5mg $52 In Stock
Pinoresinol 4-O-beta-D-glucopyranoside: 10mg Please Inquire In Stock
Pinoresinol 4-O-beta-D-glucopyranoside: 20mg Please Inquire Please Inquire
Pinoresinol 4-O-beta-D-glucopyranoside: 50mg Please Inquire Please Inquire
Pinoresinol 4-O-beta-D-glucopyranoside: 100mg Please Inquire Please Inquire
Pinoresinol 4-O-beta-D-glucopyranoside: 200mg Please Inquire Please Inquire
Pinoresinol 4-O-beta-D-glucopyranoside: 500mg Please Inquire Please Inquire
Pinoresinol 4-O-beta-D-glucopyranoside: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Pinoresinol 4-O-beta-D-glucopyranoside

3D structure

Package In Stock

Pinoresinol 4-O-beta-D-glucopyranoside

Number of papers citing our products

Chemical Properties of Pinoresinol 4-O-beta-D-glucopyranoside

Cas No. 69251-96-3 SDF Download SDF
PubChem ID 486614 Appearance Powder
Formula C26H32O11 M.Wt 520.5
Type of Compound Lignans Storage Desiccate at -20°C
Solubility Soluble in methanol; insoluble in water
Chemical Name (2S,3R,4S,5S,6R)-2-[4-[(3S,3aR,6S,6aR)-3-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES COC1=C(C=CC(=C1)C2C3COC(C3CO2)C4=CC(=C(C=C4)OC5C(C(C(C(O5)CO)O)O)O)OC)O
Standard InChIKey QLJNETOQFQXTLI-WMYFGKAISA-N
Standard InChI InChI=1S/C26H32O11/c1-32-18-7-12(3-5-16(18)28)24-14-10-35-25(15(14)11-34-24)13-4-6-17(19(8-13)33-2)36-26-23(31)22(30)21(29)20(9-27)37-26/h3-8,14-15,20-31H,9-11H2,1-2H3/t14-,15-,20+,21+,22-,23+,24+,25+,26+/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Pinoresinol 4-O-beta-D-glucopyranoside

1 Forsythia sp. 2 Pyrethrum sp.

Biological Activity of Pinoresinol 4-O-beta-D-glucopyranoside

Description(+)-Pinoresinol 4-O-beta-D-glucopyranoside revealed that the presence of a vanilloyl group in the sugar moiety of (+)-pinoresinol 4-O-[6″-O-vanilloyl]-β-D-glucopyranoside is crucial for its anti-influenza virus activity.
In vitro

In vitro anti-influenza virus activities of a new lignan glycoside from the latex of Calotropis gigantea.[Pubmed: 25102000]

PLoS One. 2014 Aug 7;9(8):e104544.

A new lignan glycoside, (+)-pinoresinol 4-O-[6″-O-vanilloyl]-β-D-glucopyranoside (1) and two known phenolic compounds, 6'-O-vanilloyltachioside (2) and 6'-O-vanilloylisotachioside (3) were isolated from the latex of Calotropis gigantea (Asclepiadaceae).
METHODS AND RESULTS:
The structure of the new compound was elucidated by using spectroscopic and chemical methods. Three isolates (1-3) and one authentic compound, (+)- Pinoresinol 4-O-beta-D-glucopyranoside, were screened for A/PR/8/34 (H1N1) inhibitory activity by cytopathic effect (CPE) inhibition assay on MDCK cells. Compound 1 showed inhibitory activity against A/PR/8/34 (H1N1). In sharp contrast, the other three compounds (2, 3 and (+)-Pinoresinol 4-O-beta-D-glucopyranoside) did not show such activity. An analysis of structure-activity relationship between 1 and (+)-Pinoresinol 4-O-beta-D-glucopyranoside revealed that the presence of a vanilloyl group in the sugar moiety of 1 is crucial for its anti-influenza virus activity. Compound 1 was further evaluated for in vitro inhibitory activities against a panel of human and avian influenza viruses by CPE inhibition assay. It showed inhibitory effect against human influenza viruses in both subtypes A and B (IC50 values around 13.4-39.8 µM with SI values of 3.7-11.4), while had no effect on avian influenza viruses. Its antiviral activity against human influenza viruses subtype A was further confirmed by plaque reduction assay. The time course assay indicated that 1 exerts its antiviral activity at the early stage of viral replication. A mechanistic study showed that 1 efficiently inhibited influenza virus-induced activation of NF-κB pathway in a dose-dependent manner, but had no effect on virus-induced activation of Raf/MEK/ERK pathway. Further studies demonstrated that nuclear translocation of transcription factor NF-κB induced by influenza virus was significantly blocked by 1, meanwhile, nuclear export of viral ribonucleoproteins was also effectively inhibited.
CONCLUSIONS:
These findings suggest that this new lignan glycoside from Calotropis gigantea, may have therapeutic potential in influenza virus infection through inhibition of NF-κB pathway and viral ribonucleoproteins nuclear export.

Pinoresinol 4-O-beta-D-glucopyranoside Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Pinoresinol 4-O-beta-D-glucopyranoside Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Pinoresinol 4-O-beta-D-glucopyranoside

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.9212 mL 9.6061 mL 19.2123 mL 38.4246 mL 48.0307 mL
5 mM 0.3842 mL 1.9212 mL 3.8425 mL 7.6849 mL 9.6061 mL
10 mM 0.1921 mL 0.9606 mL 1.9212 mL 3.8425 mL 4.8031 mL
50 mM 0.0384 mL 0.1921 mL 0.3842 mL 0.7685 mL 0.9606 mL
100 mM 0.0192 mL 0.0961 mL 0.1921 mL 0.3842 mL 0.4803 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Pinoresinol 4-O-beta-D-glucopyranoside

In vitro anti-influenza virus activities of a new lignan glycoside from the latex of Calotropis gigantea.[Pubmed:25102000]

PLoS One. 2014 Aug 7;9(8):e104544.

A new lignan glycoside, (+)-pinoresinol 4-O-[6''-O-vanilloyl]-beta-D-glucopyranoside (1) and two known phenolic compounds, 6'-O-vanilloyltachioside (2) and 6'-O-vanilloylisotachioside (3) were isolated from the latex of Calotropis gigantea (Asclepiadaceae). The structure of the new compound was elucidated by using spectroscopic and chemical methods. Three isolates (1-3) and one authentic compound, (+)-Pinoresinol 4-O-beta-D-glucopyranoside, were screened for A/PR/8/34 (H1N1) inhibitory activity by cytopathic effect (CPE) inhibition assay on MDCK cells. Compound 1 showed inhibitory activity against A/PR/8/34 (H1N1). In sharp contrast, the other three compounds (2, 3 and (+)-Pinoresinol 4-O-beta-D-glucopyranoside) did not show such activity. An analysis of structure-activity relationship between 1 and (+)-Pinoresinol 4-O-beta-D-glucopyranoside revealed that the presence of a vanilloyl group in the sugar moiety of 1 is crucial for its anti-influenza virus activity. Compound 1 was further evaluated for in vitro inhibitory activities against a panel of human and avian influenza viruses by CPE inhibition assay. It showed inhibitory effect against human influenza viruses in both subtypes A and B (IC50 values around 13.4-39.8 microM with SI values of 3.7-11.4), while had no effect on avian influenza viruses. Its antiviral activity against human influenza viruses subtype A was further confirmed by plaque reduction assay. The time course assay indicated that 1 exerts its antiviral activity at the early stage of viral replication. A mechanistic study showed that 1 efficiently inhibited influenza virus-induced activation of NF-kappaB pathway in a dose-dependent manner, but had no effect on virus-induced activation of Raf/MEK/ERK pathway. Further studies demonstrated that nuclear translocation of transcription factor NF-kappaB induced by influenza virus was significantly blocked by 1, meanwhile, nuclear export of viral ribonucleoproteins was also effectively inhibited. These findings suggest that this new lignan glycoside from Calotropis gigantea, may have therapeutic potential in influenza virus infection through inhibition of NF-kappaB pathway and viral ribonucleoproteins nuclear export.

Description

Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is the major active furofuran type lignans in Fructus Forsythiae. Pinoresinol 4-O-β-D-glucopyranoside shows antioxidant, blood pressure reducing, and cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitory effects.

Keywords:

Pinoresinol 4-O-beta-D-glucopyranoside,69251-96-3,Natural Products, buy Pinoresinol 4-O-beta-D-glucopyranoside , Pinoresinol 4-O-beta-D-glucopyranoside supplier , purchase Pinoresinol 4-O-beta-D-glucopyranoside , Pinoresinol 4-O-beta-D-glucopyranoside cost , Pinoresinol 4-O-beta-D-glucopyranoside manufacturer , order Pinoresinol 4-O-beta-D-glucopyranoside , high purity Pinoresinol 4-O-beta-D-glucopyranoside

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: